chartexchange

China’s NMPA accepts Innovent application for sintilimab combo

Pharmaceutical Technology | Oct 27, 2026 5:35 AM EDT

Innovent Biologics has received acceptance from China's NMPA to review its sintilimab and GC101 combination for advanced melanoma.

Read original article